Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics has concluded a Type A meeting with the FDA to align on the upcoming BLA resubmission for Pz-cel. The company continues to expect to resubmit the BLA in the second half of 2024.
August 12, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics has successfully concluded a Type A meeting with the FDA to align on the upcoming BLA resubmission for Pz-cel, with plans to resubmit in the second half of 2024.
The successful conclusion of the Type A meeting with the FDA is a positive regulatory step for Abeona Therapeutics, indicating progress towards the resubmission of the BLA for Pz-cel. This development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100